Live Webinar: Applications of Healthcare Large Models in Drug Discovery [AI in Healthcare Large Models Series Session 3]

To accelerate the adoption of large language model (LLM) technology in healthcare and medical scenarios, VCBeat has specially organized a series of live-streamed events under the theme “Pragmatism,” titled “Special Series on Medical Large Language Models.” This event willConducted via online live streaming, with a total of four sessions; each session will invite 2–3 leading enterprises in the field of domestic medical large language models.Focus on in-depth discussions of individual large-model application scenarios to overcome implementation challenges, connect with ecosystem resources, and facilitate greater ecosystem collaboration and supply-demand matching.

For a long time, the “Triple Ten Rule” of innovative drug development—ten years, one billion dollars, and a 10% success rate—has drawn significant attention to the progress of AI technology in empowering drug R&D and facilitating clinical trials. This trend is reshaping the R&D models and market landscape of the traditional pharmaceutical industry. By leveraging high-quality foundational data and powerful computational algorithms, AI technology can accelerate multiple stages of drug development, including target discovery, compound screening, and formulation development, thereby significantly improving R&D efficiency, reducing costs, and advancing intelligent processes. With the leapfrog development of large AI models such as ChatGPT and DeepSeek, the industry and capital markets are closely observing what disruptive transformations these models will bring to drug research and development.

Based on this,On April 24, from 19:00 to 19:45, the third session of VCBeat’s live streaming series on medical large language models, starting from “Drug R&D"Starting from this target service group, inviteLi Changqing, Co-founder and Chief Medical Officer of Egrin Pharma; Lu Yiming, Head of the Global Product R&D Division at Taimei Medical Technology; Huang Jinglin, Chief of Staff and Senior Strategy Director at Tengmai PharmaIIIPositionGuests, attending “Applications of Large AI Models in Drug Discovery and Development"Online Roundtable Discussion,Focus“AI Large Models Empowering Drug R&D from Multiple Perspectives and Across Multiple Stages”in-depth discussion on the practical implementation, regulatory oversight, and commercialization trends.

Li Changqing

Co-Founder and Chief Medical Officer of Aeglea Pharma

Holds an MHA in Hospital Administration and a PhD in Public Health from the University of Alabama at Birmingham, is a licensed physician in the United States, and previously served as a Senior Medical Review Officer at the U.S. FDA. Possesses extensive experience in new drug development across multiple therapeutic areas, having led hundreds of clinical trials and over 30 new drug applications worldwide.

Lu Yiming

Head of Global Product and R&D Division, Taimei Medical Technology

Mr. Lu Yiming holds a Bachelor’s degree in Computer Science and Technology from Shanghai Jiao Tong University and a Master’s degree in Computer Science from the University of California, Irvine. He previously worked at Microsoft’s headquarters in Redmond, USA, and served as Chief Technology Officer (CTO) at Box, a company listed on the New York Stock Exchange, and at 36Kr. With extensive experience in technical architecture and technology department management, he holds multiple U.S. patents and has published papers in top-tier conferences and journals in the fields of databases and artificial intelligence. Currently, Mr. Lu serves as the Head of Global Product and R&D at Taimei Medical Technology, where he provides middle-platform capabilities (business, technology, and data) to the company’s front-office business units, while also facilitating external connections and empowering ecosystem partners and regulatory authorities. He simultaneously oversees the research, development, operations, and management of the eCollect, eBalance, eCooperate, eArchives, and eImage systems.

Huang Jinglin

Chief of Staff and Senior Director of Strategy at Tengmai Pharma

Dr. Jinglin Huang currently serves as Chief of Staff and Senior Director of Strategy at TandemAI. Previously, she worked at McKinsey & Company, where she helped domestic and multinational companies in the pharmaceutical, medical device, and high-tech sectors across the United States and Asia formulate development strategies, plan new businesses and products, enhance operational management, implement digital transformation, and support new venture incubation, mergers and acquisitions, and partnerships. Prior to joining McKinsey, she held various positions at Amgen and the Harvard Innovation Labs. Dr. Huang holds a Ph.D. in Medical Engineering from the California Institute of Technology.

VCBeat will concurrently hold “Forum on Innovative Applications of Large Medical AI Models”, inviting guests from China’s medical AI technology enterprises, AI investors, digitalization departments of pharmaceutical companies, and themed industrial parks to attend the conference and jointly promote the development of the medical AI large model industry.

Multinational pharmaceutical companies and listed enterprises will be present, with over 10 leading domestic large model companies delivering thematic presentations; in-depth analysis of the most popular application scenarios and implementation cases to address challenges in deploying large models.《White Paper on Large Medical AI Models》Major Announcement: Providing a Value Coordinate System for Capital and Industrial Layouts of Large Medical Models; Gathering Resources from All Sectors of the Medical AI Industry to Promote Efficient Collaboration. Please scan the QR code on the poster below to register.